AviadoBio Presents Positive Preclinical Data for AVB-406 Program in Alzheimer’s Disease and Other Tauopathies at ASGCT 2026

Contributed by: Business Wire

Logo

Business Wire logo

Tags

Health
Neurology
Genetics
Clinical Trials
Pharmaceutical
Biotechnology
AviadoBio